PNH Clones for Aplastic Anemia with Immunosuppressive Therapy: A Systematic Review and Meta-Analysis
- 2 September 2020
- journal article
- review article
- Published by S. Karger AG in Acta Haematologica
- Vol. 144 (1), 34-43
- https://doi.org/10.1159/000506387
Abstract
Objectives: PNH clones, also aptly called “escape clones,” are evidence of acquired immune-mediated bone marrow failure and have a high prevalence in patients with aplastic anemia (AA). Several studies have reported contradictory results regarding the impact of PNH clones on AA patients with immunosuppression treatment, and PNH clones have not been confirmed as positive predictors of response in the AA guidelines of the British Society for Standards in Haematology. Methods: We performed a meta-analysis to address this issue by searching for articles in PubMed, EMBASE, The Cochrane Library, Web of Science, and ClinicalTrials.gov, and for abstracts from the annual meetings of the American Society of Hematology and the European Hematology Association. We included 1,236 participants from 11 cohort-controlled studies. Our primary outcome was the 6-month hematologic response with a secondary outcome of the mortality rate within 3 months. Results: A better response rate was observed in the PNH+ group than in the PNH– group (odds ratio [OR] 2.85; 95% confidence interval [CI] 2.17–3.75; p < 0.00001), and further subgroup analysis strengthened the outcome, with minor heterogeneity in non-Asian countries. In contrast, the early mortality was not significantly different between the PNH+ and PNH– groups (OR 0.54; 95% CI 0.26–1.10; p = 0.09). Conclusions: The meta-analysis suggested an evidence-based role for PNH clones in predicting a better response in AA patients with immunosuppression.Keywords
This publication has 31 references indexed in Scilit:
- Comment to "Favorable outcome of patients who have 13q deletion: a suggestion for revision of the WHO 'MDS-U' designation" Haematologica. 2012;97(12):1845-9.Haematologica, 2013
- Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemiaHaematologica, 2011
- Paroxysmal nocturnal haemoglobinuria clones in children with acquired aplastic anaemia: a prospective single centre studyBritish Journal of Haematology, 2010
- Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysisHaematologica, 2009
- Predicting response to immunosuppressive therapy and survival in severe aplastic anaemiaBritish Journal of Haematology, 2008
- Clinical impact of HLA‐DR15, a minor population of paroxysmal nocturnal haemoglobinuria‐type cells, and an aplastic anaemia‐associated autoantibody in children with acquired aplastic anaemiaBritish Journal of Haematology, 2008
- Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemiaBlood, 2006
- Coexistence of normal and clonal haemopoiesis in aplastic anaemia patients treated with immunosuppressive therapyBritish Journal of Haematology, 1999
- Relapse and clonal disease in children with aplastic anemia (AA) after immunosuppressive therapy (IST): the SAA 94 experienceKlinische Padiatrie, 1998
- Treatment of Aplastic Anemia with Antilymphocyte Globulin and Methylprednisolone with or without CyclosporineNew England Journal of Medicine, 1991